{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:06:03Z","timestamp":1769720763192,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":645,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1038\/mto.2015.6","type":"journal-article","created":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T14:35:45Z","timestamp":1430318145000},"page":"15006","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer"],"prefix":"10.1016","volume":"2","author":[{"given":"Svend O","family":"Freytag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzan","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mto.2015.6_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mto.2015.6_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/hum.1998.9.9-1323","article-title":"A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy","volume":"9","author":"Freytag","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mto.2015.6_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0360-3016(02)03005-5","article-title":"Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model","volume":"54","author":"Freytag","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mto.2015.6_bib4","first-page":"4968","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer","volume":"62","author":"Freytag","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.6_bib5","first-page":"7497","article-title":"Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer","volume":"63","author":"Freytag","year":"2003","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.6_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.mt.6300068","article-title":"Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.6_bib7","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/mt.sj.6300120","article-title":"Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.6_bib8","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/mt.2008.172","article-title":"Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate","volume":"16","author":"Barton","year":"2008","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.6_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/mt.2011.89","article-title":"Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer","volume":"19","author":"Barton","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.6_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","article-title":"Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer","volume":"89","author":"Freytag","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mto.2015.6_bib11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.mt.6300162","article-title":"Prostate cancer gene therapy clinical trials","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.6_bib12","series-title":"Gene-Based Therapies for Cancer","first-page":"33","author":"Freytag","year":"2010"},{"key":"10.1038\/mto.2015.6_bib13","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/gt.2013.40","article-title":"Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer","volume":"20","author":"Freytag","year":"2013","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.6_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mto.2015.6_bib15","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1158\/1078-0432.CCR-07-0776","article-title":"Interleukin-12: biological properties and clinical application","volume":"13","author":"Del Vecchio","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.6_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1359-6101(01)00032-6","article-title":"Interleukin-12 in anti-tumor immunity and immunotherapy","volume":"13","author":"Colombo","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1038\/mto.2015.6_bib17","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1038\/mto.2015.6_bib18","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.6_bib19","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/1078-0432.CCR-03-0304","article-title":"Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes","volume":"10","author":"van Herpen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.6_bib20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1038\/mto.2015.6_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1038\/mto.2015.6_bib22","first-page":"125","article-title":"Explanation of the decrease in alkaline phosphatase (ALKP) activity in hemolyzed blood samples from the clinical point of view: in vitro study","volume":"5","author":"Farah","year":"2012","journal-title":"Jordan J Biol Sci"},{"key":"10.1038\/mto.2015.6_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/mthe.2000.0037","article-title":"Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse","volume":"1","author":"Paielli","year":"2000","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.6_bib24","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.6_bib25","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.4049\/jimmunol.148.11.3433","article-title":"Cloning and expression of murine IL-12","volume":"148","author":"Schoenhaut","year":"1992","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.6_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/10430340152712700","article-title":"Effect of blood collection technique in mice on clinical pathology parameters","volume":"13","author":"Schnell","year":"2002","journal-title":"Hum Gene Ther"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T22:06:19Z","timestamp":1691618779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770516300080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":26,"alternative-id":["S2372770516300080"],"URL":"https:\/\/doi.org\/10.1038\/mto.2015.6","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]},"article-number":"15006"}}